Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€9.87

€9.87

2.190%
0.216
2.190%
€14.22
 
24.10.25 / Tradegate WKN: A1180P / Symbol: OCUL / Name: Ocular / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Ocular Therapeutix Inc. Stock

There is an upward development for Ocular Therapeutix Inc. compared to yesterday, with an increase of €0.22 (2.190%).
With 15 Buy predictions and not the single Sell prediction the community is currently very high on Ocular Therapeutix Inc..
With a target price of 14 € there is a positive potential of 41.84% for Ocular Therapeutix Inc. compared to the current price of 9.87 €.
So far the community has only identified positive things for Ocular Therapeutix Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Ocular Therapeutix Inc. in the next few years

Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Ocular Therapeutix Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Ocular Therapeutix Inc. 2.190% -2.711% -7.757% -4.268% 23.221% 167.697% 14.767%
Atricure Inc. 0.630% 1.387% 7.414% -48.710% -48.710% -48.710% 1.274%
Orasure Tech 2.440% -1.563% -7.353% -31.892% -26.316% -38.537% -81.739%
SI-BONE Inc 0.760% 3.937% 10.924% 14.783% 1.538% - -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When delving into the financials of Ocular (NASDAQ: OCUL) in the healthcare equipment and supplies industry, the analysis reveals a company facing significant challenges, evidenced by a bleak profitability outlook and a troubling balance sheet. The indicators present a mixed scenario, where potential exists amidst considerable financial hurdles.

Market Capitalization: Ocular holds a market capitalization of approximately $1.21 billion. This sizeable market cap suggests that the company has gained investor confidence, likely due to prospects in the healthcare domain, which can often provide robust growth opportunities.

Revenue Growth: There is a notable quarterly revenue growth year-over-year (YOY) of 10.5%. This figure indicates a positive trajectory, suggesting that the company's sales efforts and product reception in the market are gaining traction. Moreover, the total revenue reported was around $59.84 million, which, despite being modest, shows movement in the right direction.

Comments

Ocular Therapeutix (NASDAQ:OCUL) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Ratings data for OCUL provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 4.71%
Target price 17.890
Change
Ends at 02.10.26

Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
Ratings data for OCUL provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 4.42%
Target price 17.036
Change
Ends at 01.10.26

Ocular Therapeutix (NASDAQ:OCUL) had its price target raised by analysts at Needham & Company LLC from $15.00 to $20.00. They now have a "buy" rating on the stock.
Ratings data for OCUL provided by MarketBeat
Show more

News

OCUL Sales Drop 18%
OCUL Sales Drop 18%

Ocular Therapeutix (NASDAQ:OCUL), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant